Inhalation characteristics of asthmatic children (child), adults asthmatics (adult) and chronic obstructive pulmonary disease patients when they inhale through a spiromax dry powder inhaler (DPI) Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
Indacaterol/glycopyrronium (IND/GLY) is cost-effective compared with salmeterol/fluticasone (SFC) in Swedish chronic obstructive pulmonary disease (COPD) patients Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD Year: 2017
Salmeterol, added to usual therapy, is an effective bronchodilator over 12 months of treatment in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 241s Year: 2002
The influence of inhalation device for bronchodilators on the results of therapy in primary care patients with bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Asthma control or asthma severity Year: 2008
Medical personnel‘s ability to use pressurized metered dose inhaler (pMDI) in India Source: Annual Congress 2006 - The challenges of managing asthma in primary care Year: 2006
Pulmonary function response in smokers and patients with chronic obstructive lung disease (COPD) following exposure to concentrated fine (PM2.5 ) particles Source: Annual Congress 2009 - Indoor and outdoor air pollution Year: 2009
Efficacy of erdosteine (E) in the treatment of exacerbated and stable chronic bronchitis or chronic obstructive pulmonary disease (CB/COPD): a meta-analysis of individual patient data Source: Annual Congress 2009 - Drug effects in COPD Year: 2009
The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 515s Year: 2001
Exercise capacity and dyspnea challenge of adult chronic obstructive lung disease (COPD) patients when using a novel mesh nebulizer compared to traditional jet nebulizer (TJN) Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more Year: 2020
Evaluation of tiotropium rotacaps once daily in patients with chronic obstructive pulmonary disease over 4 weeks Source: Eur Respir J 2005; 26: Suppl. 49, 289s Year: 2005
Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 146s Year: 2001
Enhanced training on how to use a dry powder inhaler (DPI) improves the inhalation manoeuvre (IM) of patients with asthma (child 6–17 yrs and adult >17 yrs) or COPD and in healthy adults (HA) when they use a Spiromax® (S) and Turbuhaler® (T) DPI Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Long-term efficacy of repeated pulmonary rehabilitation programs (PRP) in chronic airway obstruction (CAO) Source: Annual Congress 2005 - Pulmonary rehabilitation: an evidence-based intervention Year: 2005
Medium dose budesonide/formoterol in fixed combination improves lung function over 2-3 weeks in patients with acute obstructive bronchitis of viral etiology Source: Annual Congress 2010 - Airway responsiveness, chronic cough and bronchiectasis: a modern approach Year: 2010
Safety and pharmacokinetics of two dose strengths of ciprofloxacin dry powder for inhalation (DPI) in patients with moderate to severe COPD Source: Annual Congress 2012 - Hot topics in respiratory infections Year: 2012
Vaccination efficacy in workers with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 107s Year: 2006
Preference and quality of life of adult chronic obstructive lung disease (COPD) patients when using a novel mesh nebulizer compared to traditional jet nebulizer (TJN) Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more Year: 2020
Phase II study of once-daily GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? Source: Eur Respir J 2002; 19: 928-935 Year: 2002
Safety of salmeterol / fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease (COPD) for one year Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002